Immune Netw.
2012 Aug;12(4):139-147.
The Past, Present, and Future of Adoptive T Cell Therapy
- Affiliations
-
- 1Cellular Immunology Laboratory, Division of Molecular and Life Science, POSTECH Biotech Center, Pohang University of Science & Technology, Pohang 790-784, Korea. ycsung@postech.ac.kr
- 2Department of Microbiology and Immunology, College of Medicine, The Catholic University of Korea, Seoul 137-701, Korea.
- 3Division of Integrative Biosciences and Biotechnology, Pohang University of Science and Technology, Pohang 790-784, Korea.
Abstract
- Although adoptive T cell therapy (ACT) has become a promising immunotherapeutic regime for cancer treatment, its effectiveness has been hindered by several inherent shortcomings regarding safety and efficacy. During the past few decades, several strategies for enhancing the efficacy of ACT have been developed and introduced in clinic. This review will summarize not only the past approaches but also the latest strategies which have been shown to enhance the anticancer activity of ACT.
MeSH Terms
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Engineering HBV-specific T cells for the treatment of HBV-related HCC and HBV infection: Past, Present, and Future. Editorial on “Genetically-modified, redirected T cells target hepatitis B surface antigen-positive hepatocytes and hepatocellular carcinoma lesions in a clinical setting”
- Engineered T Cell Receptor for Cancer Immunotherapy
- Recent Advances of Adoptive Immunotherapy to Prevent CMV Disease after Allogeneic Stem-cell Transplantation
- Current Immunotherapeutic Approaches for Malignant Gliomas
- Recent Advances and Future Directions in Immunotherapeutics for Hepatocellular Carcinoma
